/Revvity%20Inc_%20logo%20on%20phone%20and%20site%20by-%20T_Schneier%20via%20Shutterstock.jpg)
Waltham, Massachusetts-based Revvity, Inc. (RVTY) provides health sciences solutions, technologies, and services. Valued at $13.7 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas. The leading research and diagnostic firm is expected to announce its fiscal second-quarter earnings for 2024 before the market opens on Monday, Jul. 29.
Ahead of the event, analysts expect RVTY to report a profit of $1.13 per share on a diluted basis, down 6.6% from $1.21 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing on another occasion.